Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19025992 | Circuit Module for Pelvic Floor Muscle Rehabilitation Device and Pelvic Floor Muscle Rehabilitation Device | January 2025 | December 2025 | Abandon | 11 | 1 | 0 | No | No |
| 18665231 | SYSTEMS AND METHODS TO PROMOTE TISSUE HEALTH VIA ELECTRICAL STIMULATION | May 2024 | November 2025 | Allow | 18 | 3 | 0 | Yes | No |
| 18487190 | Composite Phonocardiogram Visualization on an Electronic Stethoscope Display | October 2023 | July 2025 | Abandon | 21 | 2 | 1 | Yes | No |
| 17899624 | OPTICAL DEVICE | August 2022 | November 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17879731 | FLEXIBLE ULTRA-THIN LED SKIN PATCH AND MANUFACTURING METHOD THEREOF | August 2022 | January 2026 | Allow | 42 | 1 | 0 | No | No |
| 17850500 | ELECTROCARDIOGRAM ELECTRODE APPLICATION SYSTEM | June 2022 | February 2026 | Abandon | 44 | 2 | 0 | No | No |
| 17833843 | HIGH VISUAL ACUITY, HIGH SENSITIVITY LIGHT SWITCHABLE NEURAL STIMULATOR ARRAY FOR IMPLANTABLE RETINAL PROSTHESIS | June 2022 | May 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17780773 | HUMAN BODY SENSING MAT | May 2022 | October 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17711009 | METHOD AND SYSTEM FOR MEDICAL DIAGNOSIS USING GRAPH EMBEDDINGS | March 2022 | September 2025 | Abandon | 42 | 3 | 0 | No | No |
| 17763452 | SLEEP STAGE ESTIMATION DEVICE, SLEEP STAGE ESTIMATION METHOD AND PROGRAM | March 2022 | July 2025 | Abandon | 40 | 2 | 0 | Yes | No |
| 17656034 | METHOD FOR TREATING SLEEP DISORDER BASED ON DATA AND APPARATUS FOR PERFORMING THE METHOD | March 2022 | August 2025 | Abandon | 41 | 2 | 0 | Yes | No |
| 17656156 | APPARATUSES, SYSTEMS AND METHODS FOR IMPLANTABLE STIMULATOR WITH EXTERNALLY TRAINED CLASSIFIER | March 2022 | December 2025 | Abandon | 45 | 2 | 1 | No | No |
| 17650495 | Closed Loop Control in Spinal Cord Stimulation | February 2022 | January 2026 | Allow | 47 | 4 | 0 | Yes | Yes |
| 17571509 | PORTABLE UROFLOWMETRY APPARATUS, UROFLOWMETRY AND CREATING MICTURITION CHART SYSTEM USING THE SAME, AND UROFLOWMETRY METHOD | January 2022 | March 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17619561 | System for the Treatment of Disorders Associated with Inflammation | December 2021 | August 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17611519 | FACIAL BEAUTY DEVICE AND MASK SHEET USED THEREFOR | November 2021 | September 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17522924 | ADDRESSABLE ELECTRODE ARRAY SYSTEMS, DEVICES AND METHODS | November 2021 | December 2024 | Abandon | 37 | 2 | 0 | No | No |
| 17448630 | METHODS AND SYSTEMS FOR TREATMENT OF FEEDING DISORDERS | September 2021 | December 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17439779 | RAPID NEURAL RESPONSE TELEMETRY CIRCUIT AND SYSTEM OF COCHLEAR IMPLANT | September 2021 | January 2025 | Abandon | 40 | 2 | 0 | No | No |
| 17387413 | COMPOSITE PHONOCARDIOGRAM VISUALIZATION ON AN ELECTRONIC STETHOSCOPE DISPLAY | July 2021 | November 2025 | Abandon | 51 | 3 | 1 | Yes | No |
| 17370250 | SYSTEMS AND METHODS FOR LABELING DATA IN ACTIVE IMPLANTABLE MEDICAL DEVICE SYSTEMS | July 2021 | May 2025 | Abandon | 47 | 3 | 0 | Yes | No |
| 17331061 | METHOD FOR DETERMINING A POSITION OF A LASER FOCUS OF A LASER BEAM OF AN EYE SURGICAL LASER, AS WELL AS TREATMENT APPARATUS | May 2021 | November 2024 | Allow | 42 | 2 | 0 | Yes | No |
| 17293616 | BENDING MECHANISM AND MEDICAL EQUIPMENT | May 2021 | June 2024 | Allow | 37 | 1 | 0 | No | No |
| 17319169 | DIAGNOSTICS FOR DETECTION OF ISCHEMIC HEART DISEASE | May 2021 | July 2025 | Abandon | 50 | 3 | 0 | Yes | Yes |
| 17292472 | WEARABLE APPARATUS AND METHOD FOR MONITORING MEDICAL PROPERTIES | May 2021 | June 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17227510 | MEDICAL POWER TOOL | April 2021 | March 2024 | Abandon | 35 | 1 | 0 | No | No |
| 17228139 | OPTICAL SENSOR DEVICE | April 2021 | December 2025 | Allow | 57 | 3 | 1 | Yes | No |
| 17210609 | RATCHETING HANDLE FOR MEDICAL INSTRUMENT | March 2021 | March 2024 | Allow | 35 | 0 | 1 | Yes | No |
| 17268192 | DEVICES AND METHODS FOR PERCUTANEOUS ELECTRODE IMPLANT | February 2021 | April 2024 | Allow | 38 | 0 | 1 | No | No |
| 17266798 | METHOD AND SYSTEM FOR ASSESSING EMERGENCY RISK FOR PATIENTS | February 2021 | July 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17260267 | INDWELLING HYPER-DIMENSIONAL CARDIAC PHYSIOLOGIC DATA LOGGING AND TRANSMISSION SYSTEM AND METHOD OF DOING BUSINESS | January 2021 | May 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17143026 | WIRE GRIPPING DEVICE | January 2021 | July 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17114467 | USER INTERFACE FOR A SURGICAL ROBOTIC SYSTEM | December 2020 | January 2026 | Abandon | 60 | 3 | 1 | No | No |
| 17051027 | SURGICAL ROBOT SYSTEM | October 2020 | December 2024 | Abandon | 50 | 1 | 0 | No | No |
| 17015199 | Universal tool adapter | September 2020 | December 2024 | Allow | 51 | 2 | 1 | Yes | No |
| 16931554 | MODULAR ROBOTIC SURGICAL SYSTEMS | July 2020 | December 2025 | Abandon | 60 | 4 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BAIG, RUMAISA RASHID.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BAIG, RUMAISA RASHID works in Art Unit 3796 and has examined 22 patent applications in our dataset. With an allowance rate of 31.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.
Examiner BAIG, RUMAISA RASHID's allowance rate of 31.8% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BAIG, RUMAISA RASHID receive 1.73 office actions before reaching final disposition. This places the examiner in the 37% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by BAIG, RUMAISA RASHID is 42 months. This places the examiner in the 20% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +40.2% benefit to allowance rate for applications examined by BAIG, RUMAISA RASHID. This interview benefit is in the 87% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 14.3% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 0.0% of cases where such amendments are filed. This entry rate is in the 4% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 23% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 7% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 48% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 51% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.